Evaluation and management of pulmonary hypertension in systemic sclerosis.
This review summarizes the most recent studies on pulmonary hypertension related to systemic sclerosis, emphasizing new insights into pathophysiology, identification of new markers, and advances in the diagnosis and treatment of this complication that greatly worsens the prognosis of patients with systemic sclerosis.
Preston
Ioana R
IR
Division of Pulmonary, Critical Care and Sleep, Tufts-New England Medical Center and Tufts School of Medicine, Boston, Massachusetts 02111, USA.
Hill
Nicholas S
NS
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D014665:Vasodilator Agents